Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study

about

Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study

Item

http://www.wikidata.org/entity/Q36053080

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@ast

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@en

type

Item

label

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@ast

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@en

prefLabel

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@ast

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@en

P1476

Long-Term Effectiveness and Co ...... the CORE Diabetes Model Study

@en

P2093

Guoqiang Liu

http://www.w3.org/2001/XMLSchema#string

Meimei Tian

http://www.w3.org/2001/XMLSchema#string

Sisi Liu

http://www.w3.org/2001/XMLSchema#string

Xuesong Zhang

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

Yukun Li

http://www.w3.org/2001/XMLSchema#string

P2860

Standards of Medical Care in Diabetes--2015: Summary of Revisions

The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States

The glucagon-like peptides.

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.

Standards of medical care in diabetes-2015 abridged for primary care providers.

An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.

Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

P304

e0156393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0156393

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27304904

http://www.w3.org/2001/XMLSchema#string

P921

metformin

type-2 diabetes

P932

4909290

http://www.w3.org/2001/XMLSchema#string